Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bone drug showdown: which works better for Steroid-Weakened bones?

NCT ID NCT06472050

Disease control Sponsor: Tuen Mun Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at two osteoporosis medications—romosozumab and denosumab—in 54 people who take long-term steroids and have weak bones. Participants first received either romosozumab for 12 months followed by denosumab, or denosumab alone for 24 months. Then everyone stayed on denosumab for another 2 years. The goal was to see how their spine and hip bone density changed over 4 years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Romosozumab (Evenity) and Denosumab (Prolia)
What this could lead to
If successful, this could show that switching from romosozumab to denosumab maintains or improves bone density better than denosumab alone for people on long-term steroids.
What could go wrong
This is a small, completed extension study with only 54 participants, so results may not apply to everyone. It only measures bone density, not actual fracture reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

54 people

The number who actually took part.

Started

Aug 2024

Finished

Apr 2026

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. patients who are continued on 6-monthly subcutaneous injection of DEN in either the ROMO or DEN arms after month 24 in our original RCT 2. Those who are willing to have a repeat DXA assessment at the end of 4 years. Exclusion Criteria: 1. patients who refuse to be maintained on denosumab after month 24; 2. patients who are maintained on other anti-osteoporotic drugs after month 24; and 3. patients in whom prednisolone is planned to be tapered or discontinued after month 24.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glucocorticoid-induced osteoporosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone fracture exogenous Cushing syndrome glucocorticoid-induced osteoporosis osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glucocorticoids toxicity Osteoporosis

Contacts and locations

Locations

  • Department of Medicine, Tuen Mun Hospital

    Hong Kong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.